Rationally Attenuated Vaccines for Venezuelan Equine Encephalitis Protect Against Epidemic Strains with a Single Dose release_inn45ahgljabbf6dhiobtxmdty

by Shannan L. Rossi, Kasi Russell-Lodrigue, Kenneth S. Plante, Nicholas Bergren, Rodion Gorchakov, Chad Roy, Scott Weaver

Published in Vaccines by MDPI AG.

2020   Volume 8, Issue 3, p497


Venezuelan equine encephalitis virus (VEEV) is a re-emerging virus of human, agriculture, and bioweapon threat importance. No FDA-approved treatment is available to combat Venezuelan equine encephalitis in humans, prompting the need to create a vaccine that is safe, efficacious, and cannot be replicated in the mosquito vector. Here we describe the use of a serotype ID VEEV (ZPC-738) vaccine with an internal ribosome entry site (IRES) to alter gene expression patterns. This ZPC/IRES vaccine was genetically engineered in two ways based on the position of the IRES insertion to create a vaccine that is safe and efficacious. After a single dose, both versions of the ZPC/IRES vaccine elicited neutralizing antibody responses in mice and non-human primates after a single dose, with more robust responses produced by version 2. Further, all mice and primates were protected from viremia following VEEV challenge. These vaccines were also safer in neonatal mice than the current investigational new drug vaccine, TC-83. These results show that IRES-based attenuation of alphavirus genomes consistently produce promising vaccine candidates, with VEEV/IRES version 2 showing promise for further development.
In application/xml+jats format

Archived Files and Locations

application/pdf  1.6 MB
web.archive.org (webarchive)
res.mdpi.com (publisher)
Read Archived PDF
Type  article-journal
Stage   published
Date   2020-09-02
Language   en ?
Container Metadata
Open Access Publication
In Keepers Registery
ISSN-L:  2076-393X
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 0c3886fe-5a28-4f9f-88f8-892761268907